Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Jul 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated
- 23 Aug 2018 Planned End Date changed from 31 Jul 2018 to 31 Jul 2022.